Clinical Study

Artios Novartis Omb157g23101

Posted Date: Feb 15, 2021

  • Investigator: Aram Zabeti
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy


Participant Must Be Between 18-60 That Has Been Diagnosed With Relapsing Forms Of Ms (Rms) And Secondary Progressive Ms (Spms). Must Have Ms Treatment History With A Max Of 3 Dmts.


Relapsing Multiple Sclerosis, Neurology, Secondary Progressive Multiple Sclerosis

For More Information:

Tiffany Rupert

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.